Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, primarily Alzheimer's. Its key product, ZUNVEYL, is a next-generation acetylcholinesterase inhibitor approved for mild to moderate dementia. The company also advances pre-clinical programs targeting cognitive impairment, traumatic brain injury, and other neurodegenerative conditions, leveraging innovative formulations and strong intellectual property to address unmet medical needs in aging populations.
This description was generated via AI from an annual report. Updated about 1 year ago.